SAVE THE DATE: NORDIC NANOVECTOR TO HOST CAPITAL MARKETS DAY IN OSLO, NORWAY ON 17 NOVEMBER 2015
Oslo, Norway, 17 September 2015
Nordic Nanovector ASA (OSE: NANO), a company focusing on the development and commercialisation of novel targeted therapeutics in haematology and oncology, will host a Capital Markets Day on Tuesday, 17 November 2015 in Oslo for investors, analysts and members of the press. The event will provide an opportunity to learn more about the Company’s corporate strategy, its lead product Betalutin® as a potential new treatment for non-Hodgkin’s lymphoma (NHL), and the development and commercialisation plans for this novel Antibody-Radionuclide-Conjugate (ARC), as well as future opportunities for value creation.
Presentations will be given by members of Nordic Nanovector’s senior management team and selected experts in the fields of ARCs and NHL.
The agenda and further information about the event will be posted on www.newsweb.no and on www.nordicnanovector.com on or around 15 October 2015.
Pre-register now by e-mail to email@example.com
For further information, please contact:
Tone Kvåle, Chief Financial Officer
Tel: +47 22 18 33 01
Cell: +47 91 51 95 76
About Nordic Nanovector
Nordic Nanovector is a biotech company focusing on the development and commercialisation of novel targeted therapeutics in haematology and oncology. The Company’s lead clinical-stage product opportunity is Betalutin®, the first in a new class of Antibody-Radionuclide-Conjugates (ARC) designed to improve upon and complement current options for the treatment of non-Hodgkin Lymphoma (NHL). NHL is an indication with substantial unmet medical need and orphan drug opportunities, representing a growing market worth over $12 billion by 2018.
Betalutin® comprises a tumour-seeking anti-CD37 antibody (HH1) conjugated to a low intensity radionuclide (lutetium- 177). It has shown promising efficacy and a favourable safety profile in a Phase 1/2 study in a difficult-to-treat NHL patient population. The Company is aiming at rapidly developing Betalutin® for the treatment of major types of NHL with first approval anticipated by the end of 2018.
Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets, while exploring potential distribution agreements in selected geographies. The Company is committed to developing its ARC pipeline to treat multiple selected cancer indications.
Source: Nordic Nanovector